Summarized by Masters of Longevity from PR Newswire.
Preview of late-breaking clinical trials at a cardiology meeting covering pharmacotherapy, imaging diagnostics, and device therapy for cardiomyopathy patients.
Key Takeaways
- Two randomized Phase 2 trials will report on an oral agent, tovinontrine, in reduced and preserved ejection fraction heart failure.
- CARDIO-TTRansform will present effects of eplontersen on health status and cardiac biomarkers in transthyretin amyloid cardiomyopathy.
- Real-world and trial data will be shown for cardiac contractility modulation and cardiac microcurrent therapies with one-year and six-month outcomes.
